No study locations reported - 01 Jun `26A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo

A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo

Official title: A Randomized, Double-blind, Placebo-controlled Phase Ib/II Clinical Trial of Multiple Subcutaneous Injections of GR2301 in Combination With Phototherapy to Evaluate the Tolerability, Safety, Pharmacokinetics, and Preliminary Efficacy in Trial Participants With Vitiligo

Status: Opening soon

Description:

This is a randomized, double-blind, placebo-controlled Phase Ib/II clinical trial of multiple subcutaneous injections of GR2301 in combination with phototherapy to evaluate the tolerability, safety, pharmacokinetics, and preliminary efficacy in trial participants with vitiligo. The trial will be conducted in two stages: a dose-escalation stage (Phase Ib) and an expansion cohort stage (Phase II).

Phases: Phase 1, Phase 2.

What is being studied: biologicals — GR2301 injection, Placebo.

Who can take part: ages 18 Years to 65 Years, 116 participants planned.

Enrollment status: Opening soon. The study started 01 June 2026 and is expected to finish 01 December 2028.

Contact: liaison officer.

Source: ClinicalTrials.gov, NCT07647237 (https://clinicaltrials.gov/study/NCT07647237).

Start date: June 01, 2026

Completion date: December 01, 2028

Organizer: Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Contact: liaison officer

Tel.: 021-50805988-8039

Email: shuxueye@genrixbio.com

Link: https://clinicaltrials.gov/study/NCT07647237

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions